| Authors: |
Walls GM; Department of Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, United Kingdom; Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom. Electronic address: g.walls@qub.ac.uk., Mistry H; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom., Barlesi F; Multidisciplinary Oncology & Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France; Paris Saclay University, Medical Oncology Department, Gustave Roussy, Villejuif, France., Bezjak A; Canadian Cancer Trials Group, Princess Margaret Cancer Center, Toronto, Canada., Pechoux CL; Radiation Oncology Department, Gustave Roussy, Villejuif, France., O'Brien M; Department of Medicine, Royal Marsden NHS Foundation Trust, Surrey, United Kingdom., Van Meerbeeck JP; Thoracic Oncology, Antwerp University Hospital, Edegem, Belgium., Blackhall F; Department of Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Molecular and Clinical Cancer Sciences, University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom., Faivre-Finn C; Department of Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Molecular and Clinical Cancer Sciences, University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom. |
